Kairos Pharma (KAPA) Profit After Tax (2023 - 2025)

Kairos Pharma (KAPA) has 3 years of Profit After Tax data on file, last reported at -$1.4 million in Q2 2025.

• Quarterly Profit After Tax fell 462.06% year-over-year to -$1.4 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$4.7 million (down 134.85% YoY) and the FY2025 annual result came in at -$5.4 million, down 109.26% from the prior year.
• Profit After Tax declined to -$1.4 million in Q2 2025, from -$1.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$253000.0 in Q2 2024 to a low of -$1.4 million in Q2 2025.
• A 3-year average of -$839625.0 and a median of -$1.0 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax grew 12.34% — and 2025, when it sank 462.06%.
• Tracing KAPA's Profit After Tax over 3 years: stood at -$1.1 million in 2023, then gained by 12.34% to -$980000.0 in 2024, then sank by 45.1% to -$1.4 million in 2025.
• The last three Profit After Tax figures came in at -$1.4 million (Q2 2025), -$1.3 million (Q1 2025), and -$980000.0 (Q4 2024), per Business Quant data.